MYCICLIB 100MG CAPSULE

About

Myciclib 100mg Capsule is a sophisticated targeted therapy classified as a cyclin-dependent kinase (CDK) inhibitor, specifically designed to block the activity of CDK4 and CDK6. These kinases are pivotal regulators of the cell cycle, and their aberrant activity often drives uncontrolled proliferation in cancer. By inhibiting CDK4/6, Myciclib effectively arrests cancer cells in the G1 phase, preventing their progression into the DNA synthesis (S) phase and thus halting uncontrolled cell division and tumor growth. This mechanism makes it a highly effective agent in specific oncological settings. It is predominantly indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, typically administered in combination with an aromatase inhibitor or fulvestrant. Its use aims to improve progression-free survival and enhance the efficacy of endocrine therapy in these patient populations.

Uses

• HR+, HER2- advanced breast cancer
• Metastatic breast cancer
• In combination with aromatase inhibitors
• In combination with fulvestrant

Directions For Use

Take orally once daily with food, as prescribed by your oncologist. Do not chew, crush, or open the capsule.

Benefits

• Targets specific cancer pathways.
• Improves progression-free survival.
• Effective in HR+, HER2- breast cancer.
• Oral administration for patient convenience.
• Can be used in first-line or subsequent therapy.
• Offers a non-chemotherapy option.

Side Effects

• Neutropenia (common)
• Leukopenia
• Fatigue
• Nausea
• Diarrhea
• Stomatitis
• Hair thinning
• Infections
• Thrombocytopenia
• Anemia
• Elevated liver enzymes
• Pulmonary embolism (rare)

Safety Measures

• Alcohol - Limit alcohol intake as it may worsen gastrointestinal side effects or interact with the drug's metabolism.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm; use effective contraception during treatment and for a period after.
• Breastfeeding - Advise against breastfeeding due to the potential for serious adverse reactions in breastfed infants.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustment may be necessary.
• Kidney - Use with caution in patients with severe renal impairment; dose adjustment may be required.
• Lung - Monitor for symptoms of interstitial lung disease/pneumonitis; discontinue if confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.